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The ﬁbrinolytic function of earthworm protease-III-1 (EfP-III-1) has been studied in recent years. Here, we found that EfP-III-1
acted not only in ﬁbrinogenolysis, but also in ﬁbrogenesis. We have used EfP-III-1 to hydrolyze ﬁbrinogen, and to activate plas-
minogen and prothrombin. Based on the N-terminal sequences of the hydrolytic fragments, EfP-III-1 was showed to speciﬁcally
recognize the carboxylic sites of arginine and lysine. Analyses by ﬁbrinogenolysis mapping and amino acid sequencing revealed
that the isozyme could cleave the alpha, beta, and gamma chains of ﬁbrinogen, showing a high α-ﬁbrinogenase, moderate β-
ﬁbrinogenase, and low γ-ﬁbrinogenase activities. Interestingly, EfP-III-1 activated plasminogen and released active plasmin, sug-
gesting a tPA-like function. Furthermore, EfP-III-1 showed a factor Xa-like function on prothrombin, producing alpha-thrombin.
The function in both activating prothrombin and catalyzing ﬁbrinogenolysis suggests that EfP-III-1 may play a role in the balance
between procoagulation and anticoagulation.
Copyright © 2007 Jing Zhao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Earthwormshavebeenmadeasadrug(usuallyindriedpow-
der for oral administration) to improve blood circulation
and to treat apoplectic stroke for tens of centuries. Early in
1878, Fr´ ed´ ericq found the alimentary tract of earthworm ex-
creting a type of protease [1]. As described by Charles Dar-
win in 1883, earthworm digestive ﬂuids can dissolve ﬁbrin
(see “The Formation of Vegetable Mould through the Action
of Worms”). In the 1980s, groups of ﬁbrinolytic isozymes
were isolated from diﬀerent earthworm species [2–4], such
as Eisenia fetida proteases (EfP) [5, 6]a n dLumbricus rubel-
lus proteases (LrP) [1, 7]. The isozymes of Eisenia fetida have
been puriﬁed and made into a drug in capsule to treat clot-
ting diseases. This preparation is stable and has high ﬁbri-
nolytic activity with a little side eﬀect in hemorrhage [8–
10]. Similar to LrP-III-1 [11, 12], EfP-III-1 has the highest
ﬁbrinolytic activity among the isozymes and has high sta-
bility [13]. Moreover, EfP-III-1 acts as a tissue plasmino-
gen activator (tPA)-like activator and initiates the plasmin-
antithrombus pathway [14–16]. Therefore, the structural
and functional characteristics of EfP-III-1 have become in-
teresting and signiﬁcant [10, 12, 17–20].
Recently, the crystal structure of EfP-III-1 (EFEb) at a
resolution of 2.06◦Ahasbeen solved,and thestructuralanal-
ysis shows that EfP-III-1 should be classiﬁed as a trypsin
fromearthworm[10].However,thestructureofthisisozyme
is diﬀerent from other trypsins. As a trypsin-like protease,
EfP-III-1 contains two chains: an N-pyroglutamated light
chain and an N-glycosylated heavy chain. The heavy chain
contains a novel structural motif, an eight-membered ring
resulting from a disulﬁde bridge between two neighboring
cysteineresidues,andacis-peptidebondexistsbetweenthese
two cysteine residues. The crystal structure of EfP-III-1 pro-
vides the structural basis for its high level of stability and re-
veals its complicated posttranslational modiﬁcations in the
earthworm.
In this laboratory, eight trypsin-like isozymes with ﬁb-
rinolytic activity were isolated from Eisenia fetida through
a stepwise-puriﬁed procedure: sulfate ammonia precipita-
tion, aﬃnity chromatography with a Sepharose-4B column
coupled with soybean trypsin inhibitor (SBTI), and ionic
chromatography with a DEAE-cellulose-52 column [21].
Interestingly, all the proteases were glycosylated. In the as-
say withthe substratesof trypsin, chymotrypsin, and elastase2 Journal of Biomedicine and Biotechnology
[17], EfP-III-1 was demonstrated as a trypsin-like protease.
So far, however, no detailed maps have been provided for the
protease involved in ﬁbrinogenolysis and plasminogen acti-
vation. Furthermore, the eﬀect of EfP-III-1 on procoagula-
tion has not been investigated yet. This work is concerned
with the functions of EfP-III-1 in both ﬁbrinolysis and ﬁ-
brogenesis.
2. MATERIALS AND METHODS
2.1. PuriﬁcationandassayofEfP-III-1
Ten mg of crude earthworm proteases, prepared as de-
scribed [17], was obtained from the ammonium sulfate pre-
cipitation of Eisenia fetida. EfP-III-1 was puriﬁed on a 4-
aminobenzamidine dihydrochloride-coupled Sepharose CL-
6B aﬃnity column (Pharmacia/ Pﬁzer Canada) eluted with a
gradient of denaturant (from 0.1 to 1M) through a BioRad
Gradient Maker [22]. The fractions were assayed by a chro-
mogenic substrate (from Roche Switzerland) as described
[23]. The active eluate was pooled and dialyzed against
0.01M Tris-HCl buﬀer (pH 8.0). Then the puriﬁed EfP-III-1
was lyophilized and stored at −20◦C before use. To check the
purity of the isozyme, the protein sample was resuspensed in
10mMTris-HClbuﬀer(pH8.0)andelectrophoresedon12%
SDS-PAGEs, then the gels were stained with Coomassie blue
and silver, respectively. The protein concentration was deter-
mined by the bicinchoninic acid (BCA) protein assay with
bovine serum albumin as the standard (Pierce, Ill, USA).
The ﬁbrinolytic activity was measured by the light scat-
tering method as described by Zhou et al. [24]. The isozyme
(0.1μM ﬁnal concentration) was incubated with ﬁbrinogen
(0.25mg/mL ﬁnal concentration) in 0.05M Tris-HCl buﬀer
(pH 7.4) at 25◦C for 10 minutes. Then thrombin (6U/mL,
Sigma Co., Mo, USA) was added to the mixture, followed
by measurement of the Rayleigh-light scattering at 480nm
on a ﬂuorescence spectrophotometer (Hitachi F-4500). One
enzymatic unit was deﬁned as the amount of enzyme caus-
ing the conversion of 1μMo fs u b s t r a t ep e rm i n u t ep e rm g
of protein at 25◦C. The standard earthworm protease with a
speciﬁc activity of 2.5 × 103 U (Chinese National Pharma-
copoeia) was purchased from the Institute for the National
Control of Pharmacological and Biological Products, China.
2.2. Hydrolysisofﬁbrinogen,plasminogen,and
prothrombinbyEfP-III-1
EfP-III-1 (0.1μM ﬁnal concentration) was incubated with
human ﬁbrinogen, plasminogen, or prothrombin (2mg/mL
ﬁnal concentration, Sigma Co., Mo, USA) in 0.05M Tris-
HCl (pH 8.3) at 25◦C. Aliquots were taken at diﬀerent time
intervals for SDS-PAGE, each of the bands was transferred
onto a polyvinylidene diﬂuoride membrane (Gelman, USA)
and then each band was cut oﬀ from the membrane for the
amino acid sequencing [25]. On the basis of the N-terminal
sequence of each digested fragment, the cleavage sites were
obtained by reference against the complete amino acid se-
quences of human ﬁbrinogen [26], prothrombin [27], and
bovine plasminogen [28]. The immobilized enzyme, pre-
pared as described [20, 29], was also used for the hydrolysis.
Fifty microliters of Sepharose CL-6B coupled with EfP-III-1
was put in an eppendorf tube (0.5mL). Fibrinogen (1mg/mL
ﬁnal concentration) was dissolved in Tris-HCl buﬀer (pH
8.3), added to the eppendorf tube (total volume 200μL), and
placed on a shaker at 25◦C. Aliquots were taken by spinning
downthereactionmixtureatdiﬀerenttimeintervals,andthe
supernatants (20μL) were subjected to electrophoresis and
amino acid sequencing.
2.3. AssaysofEfP-III-1,plasmin,andthrombin
The activities of EfP-III-1, plasminogen, and prothrombin
were measured by the light scattering intensity on a ﬂuores-
cence spectrophotometer (Hitachi F-4500). (I) Fibrogenesis:
ﬁbrinogen (2.5mg/mL ﬁnal concentration) was incubated in
0.05M Tris-HCl buﬀer (pH 7.4) at 25◦Cf o r1 0m i n u t e sb e -
fore addition of thrombin (0.2U), followed by the measure-
ment of the Rayleigh-light scattering at 480nm [24]. (II) As-
say of EfP-III-1: conditions were as for (I), except that EfP-
III-1 (0.1μM as ﬁnal concentration) and thrombin were both
added to ﬁbrinogen. (III) Activation of plasminongen: con-
ditions were referred to (II), except that plasminogen (3U)
was incubated with EfP-III-1 at 25◦C for 10 minutes, and
then added to ﬁbrinogen in the presence of thrombin. (IV)
Activation of prothrombin: instead of thrombin, prothrom-
bin (1mg/mL) was incubated with EfP-III-1 at 25◦Cf o r1 0
minutes and added into ﬁbrinogen under the same condi-
tions. Prothrombin without the incubation was used as con-
trol.
2.4. Transmissionelectronmicroscopy
EfP-III-1 (0.1μM ﬁnal concentration) was incubated with
ﬁbrinogen or prothrombin (2mg/mL ﬁnal concentration)
for 30 minutes at 25◦C. Aliquots (10μL) were observed by
electron microscopy. Samples were adsorbed (0.25–15 min-
utes) onto 300-mesh Formvar /carbon-coated copper grids.
The resultant grids were washed with water, stained with 2%
uranyl acetate (1 minute), washed again with water, blotted
dry, and viewed in a JEOL JSM-5600 electron microscope
operated at 65kV (Japan Electron Optics Laboratory Co.,
Ltd., Japan). Random images from each sample were cap-
tured onlm at 5000- to 50000-fold magnication, digitized,
calibrated, and imported into Optimas 6.5.1 for quantitation
of ﬁlament length and number as described previously [30].
3. RESULTS
3.1. PuriﬁcationandassayofEfP-III-1
EfP-III-1 was puriﬁed by the aﬃnity chromatography and
it showed a single protein band on the gel with an appar-
ent molecular mass of ∼34kd after puriﬁcation (Figure 1).
Light scattering assay showed that the speciﬁc activity of
the puriﬁed enzyme was 33 × 104 U. Sequencing of theJing Zhao et al. 3
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Figure 1: Puriﬁcation of EfP-III-1. EfP-III-1 (∼34kd, lane 1) after
puriﬁcationwaselectrophoresedona12%SDS-PAGE.Thenthegel
was stained with Coomassie blue (a) or silver (b). M represents the
low-molecular-mass protein markers.
N-terminalregionofEfP-III-1revealedaminoacidsequence
identical to LrP-III-1 (IVGGIEAR...) [12]. The unique se-
quence also demonstrated the high purity of EfP-III-1.
3.2. Hydrolysisofﬁbrinandﬁbrinogen
In order to investigate the ﬁbrinolytic activity of EfP-III-
1, we used transmission electron microscopy to observe the
morphological changes when ﬁbrin was incubated with the
protease. Fibrogenesis was clearly detected when thrombin
was incubated with ﬁbrinogen as shown in Figure 2(c).N o
observable ﬁbrils could be detected after the incubation of
ﬁbrin with EfP-III-1 (Figure 2(a)). EfP-III-1 alone as a con-
trol also exhibited no ﬁbrils under the electronic microscope
(Figure 2(b)). This observation suggests that EfP-III-1 has a
high ﬁbrinolytic activity.
Furthermore, we hydrolyzed ﬁbrinogen in the presence
of EfP-III-1 to reveal the map of the hydrolysis in which six
major distinct fragments with diﬀerent apparent molecular
masses (42, 31, 28, 25, 21, and 13kd, resp.) have been found
(Figures 2(d), 2(e)). On the SDS-PAGE, F-b appeared at the
initial stage of digestion, followed by the appearance of F-
d, F-e, F-a, F-f, and F-g whose band densities in the gel in-
creased with time, and no further degradation could be de-
tected when the reaction was prolonged to over 120 minutes
(Figures 2(d), 2(e)). This observation suggests that these ﬁve
products were stable under the assay conditions. Moreover,
another stable band called F-c contains at least two peptides.
As exhibited in Table 1, F-d, F-e, and F-f were hydrolytic
products from the α-chain of ﬁbrinogen with cleavage sites
at R252-G253,R 19-V20,a n dK 429-V430, respectively; F-a and F-
bc a m ef r o mγ-chain and contained ∼410 and ∼300 amino
acid residues, respectively. It should be noted that α-chain
was cleaved so rapidly (lane 3, Figure 2(d)) that the band
disappearedwithin5minutesundersuchconditions. Conse-
quently, hydrolysis of α-chain was further carried out using
immobilized EfP-III-1 (Figure 2(f)). The density of α-chain
band in the gel gradually decreased during the hydrolysis. As
shown in Figure 2(g), four distinct fragments (F-a’, F-b’, F-
c’, and F-d’) were released, with diﬀerent apparent molecular
Table 1: Cleavage sites on ﬁbrinogen, plasminogen, and prothrom-
bin by EfP-III-1.
Fragment EfP-III-1
Fibrinogen∗ Plasminogen∗∗ Prothrombin∗∗∗
a γ-Y1VATR D1LLDD PR3 ↓ ANTF
b γ-Y1VATR GR557 ↓ IVGG PR158 ↓ SEGS
c— — —
d α-TR252 ↓ GGST — —
e α-PR19 ↓ VVER — PR158 ↓ SEGS
f α-EK429 ↓ VTSG — GR274 ↓ TATS
g—— E R 396 ↓ NIEK
h—— P R 287 ↓ TFGS
i— — P R 3 ↓ ANTF
∗, ∗∗,a n d∗∗∗ indicate that the amino acid sequences are referred
to in [25–27], respectively.
masses (33, 31, 28, and 22kd). With the same N-terminus
as the intact α-chain [26], F-a’ was initially released in 5
minutes during the reaction. The other three fragments had
an identical cleavage site at R19-V20. According to the den-
sities of the protein bands on the SDS-PAGE, hydrolysis of
α-chain was the fastest, and hydrolysis of β-chain was faster
than that of γ-chain. This indicated that EfP-III-1 possesses
strong α-ﬁbrinogenase, moderate β-ﬁbrinogenase, and weak
γ-ﬁbrinogenase activities.
The light scattering assay was carried out to detect
whether EfP-III-1 could cleave ﬁbrinogen. Compared with
the changes in the intensity of light scattering of the mixture
containing ﬁbrinogen and thrombin (curve 1, Figure 2(h)),
the ﬁbrin formation was clearly repressed when EfP-III-1
was added (curve 2, Figure 2(h)). To investigate which is the
initial digestion target of the protease, ﬁbrinogen or ﬁbrin,
we preincubated ﬁbrinogen with EfP-III-1 for 10 minutes,
and then added thrombin. As shown in Figure 2(h), the in-
hibition of ﬁbrogenesis could be observed in the presence
of EfP-III-1, regardless of preincubation with ﬁbrinogen or
not. However, the relaxation time was remarkably prolonged
(∼100 seconds) when the protease was preincubated with
ﬁbrinogen (curve 3, Figure 2(h)). The inhibition of ﬁbrin
formation could be distinctly delayed, suggesting that EfP-
III-1 preferably cleaved ﬁbrinogen under such conditions.
3.3. Activationofplasminogen
To check the eﬀect of EfP-III-1 on plasminogen, we used
EfP-III-1toactivateplasminogenandobservedtworesultant
fragments P-a and P-b (Figure 3, apparent molecular masses:
∼60 and ∼30kd, resp.). Cleavage at R557-I558 resulted in the
releaseofP-b(Figures3(a),3(b)),whoseﬁrstsixaminoacids
were identical to those of the catalyticdomain (ormicroplas-
minogen) of activated plasmin [28]. This cleavage site (R557-
I558) was also recognized by tPA (Figure 3(c)).4 Journal of Biomedicine and Biotechnology
0.1μm
(a)
0.1μm
(b)
1.0μm
(c)
97400
66200
43000
31000
20100
14400
α
β
γ
F-a
F-b
F-c
F-d
F-e
F-f
M 1234567
(d)
N
N
N
N
N
R252 G
R19 V
K429 V
610
461
427
F-a
F-b
F-d
F-e
F-f
(e)
M123 4567
66200
43000
31000
α
β
γ
F-a’
F-b’
F-c’
F-d’
(f)
N
N
R19
R19
R19
V
V
V
610 α
F-a’
F-b’
F-c’
F-d’
(g)
1000
500
0
0 100 200 300 400 500 600
4
1
2
3
Time (s)
I
n
t
e
n
s
i
t
y
(
4
8
0
n
m
)
(h)
429 252 19 19 252 429
Fibrinogen
51 17 17 51
α
β
γ
α
β
γ
Fibrinogen fragments
EfP-III-1
??
(i)
Figure 2: Hydrolysis of ﬁbrinogen by EfP-III-1. EfP-III-1 (0.1μM ﬁnal concentration) was incubated with human ﬁbrinogen (2mg/mL in
50mM Tris-HCl buﬀer, pH 7.4) at 25◦C. (a–c) Fibrinolysis in the presence of EfP-III-1 (a) was detected by electron microscopy. EfP-III-1
(b) and ﬁbrin alone (c) were used as controls. (d,e) 12% SDS-PAGE showing ﬁbrinolysis in the presence of EfP-III-1 (d). M: low-molecular-
mass protein markers; lane 1: ﬁbrinogen which consists of three polypeptide chains: α (66kd), β (54kd), and γ chain (48kd) as control; lanes
2 through 7: aliquots were taken at 0, 5, 15, 30, 60, and 120 minutes during the hydrolysis. (e) The ﬁbrinolytic fragments (F-a to F-f) in
the presence of EfP-III-1 (e). (f,g) ﬁbrinolysis in the presence of immobilized EfP-III-1 under the same conditions. α-Fibrinogen fragments
were indicated by F-a’ to F-d’ (g). Fibrinolytic activity (2.5mg/mL, 10 minutes, 25◦C) was measured by light scattering assay (h). Thrombin
was added to ﬁbrinogen in the absence of EfP-III-1 as a control (curve 1); both EfP-III-1 and thrombin were added to ﬁbrinogen at the same
time (curve 2); EfP-III-1 was incubated with ﬁbrinogen at 25◦C for 10 minutes before thrombin was added (curve 3), and Tris-HCl buﬀer
as a negative control (curve 4). EfP-III-1 cuts at R19-V20 and destroys the N-terminal 35-residue stretch (black) which is the key recognition
motif for thrombin (i), according to C. Fuss et al. [31].Jing Zhao et al. 5
Table 2: Activities of ﬁbrinogen, plasminogen, and prothrombin.
Samples
Relative activity Fibrin formation
(%, mean ± SD)∗ (%, mean ± SD)∗∗
Fibrinogen +
thrombin
100 ±29.9 100 ±3.5
Fibrinogen +
thrombin +
EfP-III-1
38.6 ±1.87 7 .8 ±3.8
Fibrinogen +
thrombin +
plasminogen
81.1 ±79.96 9 .9 ±3.6
Fibrinogen +
thrombin +
EfP-III-1 +
plasminogen∗∗∗
27 ±9.95 .3 ±2.4
EfP-III-1 +
prothrombin +
ﬁbrinogen
31.9 ±1.55 2 .9 ±2.9
Prothrombin +
ﬁbrinogen
4.2 ±2.84 .9 ±2.9
∗Relative activity was based on the max slope of the reaction curve.
∗∗Fibrin formation was calculated with the intensity of the sample
at 10 minutes.
∗∗∗Refer to Figure 3(d), line 2.
The activation of plasminogen by EfP-III-1 was assayed
with the light scattering method (Figure 3(d)). As shown in
Table 2, the relative light scattering intensity of the reaction
mixture (ﬁbrinogen and thrombin) reached 77.8 ± 3.8( % )
in 10 minutes when EfP-III-1 was added. In particular, the
light scattering intensity remarkably decreased (5.3 ± 2.4%)
in the presence of both EfP-III-1 and plasminogen, though
the intensity increased initially. Although the ﬁbrin forma-
tion reached 69.9 ± 3.6 (%) when plasminogen was present
alone, the relative ﬁbrogenesis activity (81.1 ± 7.9%) did
not markedly decrease under the same conditions. This sug-
gested that EfP-III-1 activated plasminogen and released ac-
tive plasmin.
3.4. Activationofprothrombin
So far, we have obtained evidence demonstrating the ef-
fect of the earthworm protease on ﬁbrinolysis and activa-
tion of plasminogen. We further wondered whether EfP-III-
1 was involved in procoagulation pathway. By electron mi-
croscopy, it is obviously exhibited that some ﬁbrin deposits
were formed from ﬁbrinogen in the presence of prothrom-
bin and EfP-III-1 (Figures 4(a), 4(b)). The result of elec-
trophoresis showed that eight major hydrolytic fragments
were released after prothrombin was incubated with EfP-III-
1 (Figures 4(d), 4(e)). As shown in Figure 4(c),ﬁ b r i nf o r -
mation was increased in the presence of both prothrom-
bin and EfP-III-1. However, ﬁbrin was hardly produced
when prothrombin alone was added to ﬁbrinogen (curve 4,
Figure 4(c)). This suggested that active thrombin was re-
leased during the incubation of prothrombin with EfP-III-1.
4. DISCUSSION
The α-chain of ﬁbrinogen plays an important role in ﬁb-
rin formation during the activation of ﬁbrinogen to ﬁbrin
by thrombin (Figure 2(i)). The 35-residue stretch (G17 to
M51) in the N-terminal region is a key recognition motif for
thrombin [32]. Meanwhile, this stretch is essential for ﬁbrin
monomers to associate with each other, and to produce ﬁb-
rin ﬁbrils. We employed the immobilization of EfP-III-1 to
hydrolyze the α-chain of ﬁbrinogen (Figure 2(f), 2(g)). Use
ofimmobilizedenzymeisbasedonthefollowingreasons.(1)
Hydrolysisofα-chainwasarapidprocedureresultinginare-
lease of transient fragments, which could hardly be detected.
(2) The immobilization of protease allows us to exclude the
eﬀectsduetoresidualactivityofEfP-III-1.(3)Afterimmobi-
lization, theactivityofEfP-III-1decreasedto40%–50%, and
the enzyme molecule became more resistant to heat, acidic
and basic conditions, and denaturants [29]. (4) More impor-
tantly, the immobilization of protease enables us to control
the reaction easily and to obtain reproducible results. (5) For
EfP-III-1, immobilization did not change its substrate speci-
ﬁcity(datanotshown).Asaresult,wefoundthatthepeptide
bond of R19-V20 was a cleavage site on α-chain, and the site
was close to R16-G17 recognized by thrombin [33], it may de-
stroytherecognitionstretchandobstructthepolymerization
between ﬁbrins.
Besides R19-V20, the α-chain of ﬁbrinogen has been cut
by EfP-III-1 at other sites. According to the N-terminal se-
quencing of F-d and F-f, the cleavage sites were located at
R252-G and K429-V. Moreover, the sites were presumably lo-
c a t e da r o u n dR 334-P335 (F-a’), R289-N290 (F-b’), R252-G253 (F-
c’), and R199-Q200 (F-d’) based on that EfP-III-1 speciﬁcally
recognized the carboxylic sites of arginine and lysine which
were demonstrated by the N-terminal sequencing of all the
detected hydrolytic fragments (Table 1).
In addition, the C-terminal region of the γ-chain of ﬁb-
rinogen was also cleaved by the protease, producing F-a, F-
b, and some small undetectable peptides. Presumably, the
hydrolytic sites in the C-terminal region could be located
around R419-P420 (F-a) and K302-F303 (F-b). Hydrolysis at
these two predicted sites may also obstruct ﬁbrin formation
[34], due to the fact that the C-terminal region of ﬁbrinogen
is involved in several functional interactions, including ﬁbrin
polymerization [33]. Note that the enzyme digested ﬁbrino-
gen at multiple hydrolytic sites, leading to a remarkable de-
crease in ﬁbrinogen concentration. As described by Dempﬂe
et al. [35]a n dB o v i l le ta l .[ 36], the decrease of ﬁbrinogen
leads to an anticoagulation eﬀect in circulation.
In our experiments, no fragment from β-chain could be
detectedinthepresenceofbothnativeandimmobilizedEfP-
III-1 under the conditions. According to the amino acid se-
quence, β-ﬁbrinogen is rich in arginine and lysine residues,
which are probably vulnerable to EfP-III-1. Thus, it is likely
that the β-chain of ﬁbrinogen was hydrolyzed and the de-
graded bands disappeared within 15 minutes after addition6 Journal of Biomedicine and Biotechnology
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Figure 3: Activation of plasminogen by EfP-III-1. Plasminogen (2mg/mL ﬁnal concentration) dissolved in 50mM Tris-HCl buﬀer (pH
7.4) was incubated with EfP-III-1 at 25◦C. Aliquots were taken at diﬀerent time intervals, and loaded on SDS-PAGE (12%) (a). M shows
low-molecular-mass protein markers; lane 1: plasminogen as control; lanes 2 through 6 represented the hydrolyzed fragments after 2, 5, 15,
30, and 60 minutes. Cleavage of plasminogen after one-hour incubation with EfP-III-1 at 25◦C (b) represented the digested fragments P-a
and P-b (catalytic domain or micropalsminogen). Plasminogen in the presence of tPA (0.1μM ﬁnal concentration) was used as a control (c).
Lanes 1 through 3: plasminogen alone, with tPA, or with EfP-III-1; lane 4: tPA alone, and lane 5: EfP-III-1 alone. Enzymatic activity was
measured by light scattering assay (d). Thrombin was added to ﬁbrinogen in the presence of EfP-III-1 (curve 4, with plasminogen; curve 2,
without plasminogen), and in the absence of EfP-III-1 (curve 3 with plasminogen). Tris-HCl buﬀe r( c u r v e5 )w a su s e da sc o n t r o l .
of EfP-III-1. In addition, the protease eﬃciently cleaves the
α-,β-,andγ-chainsofﬁbrinogenatmultiplesitesinboththe
N-terminalandC-terminalregions. However,thehydrolyza-
tion of α-chain is faster than that of β-chain, and much faster
than that of γ-chain under the same conditions (Figure 2).
This indicates that EfP-III-1 acts as a strong α-ﬁbrinogenase,
am o d e r a t eβ-ﬁbrinogenase, and a weak γ-ﬁbrinogenase.
The ﬁbrinolytic system contains a proenzyme plasmino-
gen which is converted to active enzyme plasmin by the ac-
tion of plasminogen activators. Plasminogen activation by
tPA is the most important mechanism in removing ﬁbrin ex-
cess [37]. tPA speciﬁcally recognizes R557-I558 on plasmino-
gen and releases active plasmin. The cleavage site on plas-
minogenbyEfP-III-1wasthesameastPA(Figure 3(a),3(b))
[28], and no other cleavage sites could be detected under our
assay conditions. This indicates that EfP-III-1 is a tPA-like
protease.
Eightmajorhydrolyticfragmentswerereleasedafterpro-
thrombin was incubated with EfP-III-1 (Figures 4(d), 4(e)).
Theapparentmolecularmassesofthefragments(fromT-ato
T-i) were approximately 70, 52, 48, 46, 37, 33, 29, and 25kd,
respectively. The N-terminal sequences of the eight frag-
ments indicated that EfP-III-1 recognized peptidyl bonds at
R3-A4 (T-a, T-g), R158-S159 (T-e), R274-T275 (T-f), R396-N397
(T-g, detectable in both T-e and T-f), and R287-T288 (T-h).
On the basis of the molecular masses of T-e (∼35kd) and T-i
(∼25kda), we estimated that the cleavage sites at C-terminus
w e r el o c a t e da r o u n dR 493-P494 and R243-N244.
The coagulation cascade culminates in the conversion of
prothrombin to active thrombin. This reaction is catalyzed
by a multicomponent complex prothrombinase [33, 38]. In
the physiological environment, the activation of prothrom-
bin by factor Xa generates the thrombin catalytic sites, and
cleavage at R274 and R320 is required for thrombin forma-
tion [27, 39, 40]. In one pathway, human prothrombin is
converted relatively slowly to α-thrombin (274–287) in the
presence of factor Xa and Ca2+ ions by the initial cleavage
at residue R274 (consequently producing fragment 1.2 and
prethrombin 2), followed by cleavage of prethrombin 2 at
R320 (accordingly generating α-thrombin). In our experi-
ments, EfP-III-1 degraded prothrombin at R274 in the ab-
sence of Ca2+, and released prethrombin 2 (T-f, Figure 4(e)).Jing Zhao et al. 7
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Figure 4: Activation of prothrombin by EfP-III-1. Prothrombin (2mg/mL ﬁnal concentration) in 50mM Tris-HCl buﬀer (pH 7.4) was
incubated with (a) or without (b) EfP-III-1 at 25◦C, and then added into ﬁbrinogen and observed by electron microscopy. Activation of
EfP-III-1 on prothrombin was measured by light scattering assay (c). Thrombin was added to ﬁbrinogen in the absence of EfP-III-1 as a
control (curve 1); prothrombin (curve 3) or thrombin (curve 2) was incubated with EfP-III-1 before addition to ﬁbrinogen; prothrombin
(curve 4) or EfP-III-1 (curve 5) was added to ﬁbrinogen as controls, and Tris-HCl buﬀer as a negative control (curve 6). Prothrombin in the
presenceofEfP-III-1waselectrophoresedon12%SDS-PAGE(d).M:low-molecular-massproteinmarkers;lane1:prothrombinalone;lanes
2 through 7: hydrolyzed products after 0, 5, 15, 30, 60, 120 minutes, respectively. T-a to T-i represent the digested fragments of prothrombin
in the presence of EfP-III-1 (e). Diagrammatic representation of prothrombin activation products produced by incubation with EfP-III-1
was shown in (f).
Cleavage at R287 produced α-thrombin (Figure 4(f)). Similar
to the preference for residue N397 by thrombin, which pro-
duces the β-thrombin-like fragments [41], EfP-III-1 cleaves
at residue R396. As shown in Figure 4(c), the activation of
prothrombin by EfP-III-1 was time-dependent, and pro-
thrombin was ﬁrst degraded at R274 similar to the activation
byfactorXa.Furthermore,cleavageatR287 onprethrombin2
released active α-thrombin for ﬁbrogenesis [41]. Thus, EfP-
III-1 had a prothrombinase-like function in activating pro-
thrombin to produce α-thrombin.8 Journal of Biomedicine and Biotechnology
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Figure 5: Roles of EfP-III-1 in procoagulation and anticoagula-
tion. EfP-III-1 degrades ﬁbrin(ogen) and activates not only plas-
minogen but also prothrombin. Activation is indicated by dashed
lines, and degradation is indicated by dotted lines.
One problem we noted in our experiments was that F-
c from ﬁbrinogen was a mixture containing at least two
peptides (Figure 2(d)), and so were T-c and T-d from pro-
thrombin (Figure 4(d)). We have run SDS-PAGEs under
both reducing and nonreducing conditions, but the mixed
peptides could not be separated. There may be two reasons:
(1) the molecular masses of the mixed peptides were similar,
and/or (2) they were polymerized with each other and could
not be separated with SDS, DTT, and β-mercaptoethanol.
Based on our data, the roles of EfP-III-1 in procoag-
ulation and anticoagulation can be summarized as follows
(Figure 5): (1) to degrade ﬁbrinogen and ﬁbrin at both the
N-terminalandC-terminalregions(Figure 2);(2)toactivate
PLgandreleaseactiveplasmin(Figure 3);and(3)toactinan
Xa-like manner (Figure 4).
A clinical study of cerebral infarction has showed that
earthworm proteases decreased some stroke scores in com-
parison with control groups [42]. According to clinical ob-
servations [38, 42–44], the activated partial thromboplas-
tic time was prolonged, tPA activity and D-dimer levels in-
creased, and the concentration of ﬁbrinogen in blood de-
creased signiﬁcantly. In recent years, the mixture of earth-
worm proteases including EfP-III-1 has been made as an
orally administered ﬁbrinolytic agent to prevent and treat
clotting diseases [11, 14, 45]. Compared with other drugs
such as hirudin [46], tPA [47] and UK [48], “Lumbrokinase”
(containing EfP-III-1) has relatively low side eﬀects such as
hemorrhage complications (∼2%) [42]. EfP-III-1, involving
both ﬁbrinolysis and ﬁbrogensis, may play a role in balanc-
ing coagulation and anticoagulation in circulation. This may
be one explanation for the observed low incidence of hem-
orrhage complications in clinical applications of earthworm
proteases.
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